Intellia Pharmaceuticals, Inc. is a genome editing firm that is primarily concerned with the creation of therapeutics. The company’s in vivo programmes include NTLA-2001, which is currently in a Phase 1 clinical trial for the treatment of transthyretin amyloidosis, and NTLA-2002, which is being studied for the treatment of hereditary angioedema. The company also has other liver-focused programmes.
Which include hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency, among others The company’s ex vivo pipeline includes NTLA-5001, which is being developed for the treatment of acute myeloid leukaemia, as well as proprietary projects that are being developed for the treatment of different oncological and autoimmune illnesses.
The CRISPR/Cas9 system, which is composed of Clustered, Regularly Interspaced Short Palindromic Repeats and the Cas9 system, is also included in the set of tools available. Novartis Institutes for Bio Medical Research, Inc. has a licence and collaboration agreement with Intellia Therapeutics, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. Intellia also has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment.
The pricing of an underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $145.00 per share was announced today by Editas Medicine, a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo. The offering was made at a public offering price of $145.00 per share.
A 30-day option to acquire an additional 620,689 shares of Intellia common stock was also provided to the underwriters by Intellia to encourage them to participate in the offering. Prior to subtracting underwriting discounts and commissions as well as offering expenses, it is anticipated that the total proceeds from the offering will be approximately $600 million, excluding any proceeds from the exercise of the underwriters’ option to acquire additional shares. Intellia intends to sell all of the shares that are being offered in the offering.
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, and Barclays are serving as joint book-running managers for the offering on behalf of the underwriters. For this offering, Truist Securities is serving as co-manager with Morgan Stanley. It is anticipated that the offering will close on or about July 2, 2021, subject to the satisfaction of normal closing conditions.
Read More:- Twitter Stock: Should You Invest Or Not?
Those who wish to purchase Intellia’s common stock should do so in accordance with the terms of a valid shelf registration statement that was previously filed with the United States Securities and Exchange Commission (SEC). On June 28, 2021, the Securities and Exchange Commission (SEC) received and approved a preliminary prospectus supplement and supporting prospectus pertaining to and outlining the parameters of the offering.
Final prospectus supplement and accompanying prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282,
Attention: Prospectus Department, by phone at (866) 471-2526, or by email at firstname.lastname@example.org; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, SVB Leerink LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6105, or by email at email@example.com; or Barclays Capital Inc., by mail at c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5345; or by email at
Neither this press release nor the solicitation of an offer to buy these securities shall be construed as an offer to sell or the solicitation of an offer to buy these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of such state or jurisdiction.
Read More:- How to Start Invest in Stocks
Intellia Therapeutics is a biotechnology company. Using CRISPR/Cas9 technology, Intellia Treatments, a leading clinical-stage genome editing business, is creating innovative, possibly curative therapeutics for a variety of diseases.
According to the Private Securities Litigation Reform Act of 1995, as amended, certain statements in this news release constitute forward-looking statements; these include comments about Intellia’s planned public offering and other statements on Intellia’s future prospects.
Forward-looking statements are identified by the use of the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” and similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements about future events that are not yet known.
Unless otherwise stated, any forward-looking statements in this press release, such as the intended offering terms, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that could cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release.
These factors include, but are not limited to, uncertainties related to market conditions and the completion of the proposed offering. Intellia’s most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus relatio n are described in greater detail in the section entitled “Risk Factors.”
Unless otherwise stated, any forward-looking statements contained in this news release represent Intellia’s opinions only as of the date of this press release and should not be relied upon as representing Intellia’s views as of any future date or time. Intellia expressly disclaims any responsibility to update any forward-looking statements, except to the extent required by applicable legislation.